P28R: A new therapeutic cancer strategy based on the discovery of a novel immunoregulatory mechanism
| Reference number | |
| Coordinator | CanImGuide Therapeutics AB |
| Funding from Vinnova | SEK 500 000 |
| Project duration | July 2017 - November 2017 |
| Status | Completed |
Purpose and goal
The aim of the project was to analyze and evaluate the clinical and market feasibility of P28R: a new therapeutic cancer strategy based on the discovery of a novel immunoregulatory mechanism. During the project, we have also defined all details related to the planned phase I and II clinical validation. The set goals were satisfactorily fulfilled.
Expected results and effects
In the project, we have confirmed the clinical and market feasibility of P28R as well as defined all details related to the planned phase I and II clinical validation. The results of our analyzes and assessments will provide a basis for our strategic decisions related to the development of the therapy.
Planned approach and implementation
During the course of the project, we have performed an advanced market analysis including, for instance, the competitive landscape, user needs and regulatory aspects. We have also identified potential partners for the planned out-licensing deal and defined the company´s financial expectations connected to it. In addition, we have developed a plan for the following phase I and II clinical validation that will be a significant step towards commercialization of the therapy.